Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35171
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rankin J.M. | en |
dc.contributor.author | Nedkoff L. | en |
dc.contributor.author | Arnet I. | en |
dc.contributor.author | Kilkenny M.F. | en |
dc.contributor.author | Sanfilippo F.M. | en |
dc.contributor.author | Greenland M. | en |
dc.contributor.author | Knuiman M.W. | en |
dc.contributor.author | Hung J. | en |
dc.date.accessioned | 2021-05-14T11:52:42Z | en |
dc.date.available | 2021-05-14T11:52:42Z | en |
dc.date.copyright | 2020 | en |
dc.date.created | 20201202 | en |
dc.date.issued | 2020-12-02 | en |
dc.identifier.citation | Scientific reports. 10 (1) (pp 4315), 2020. Date of Publication: 09 Mar 2020. | en |
dc.identifier.issn | 2045-2322 (electronic) | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/35171 | en |
dc.description.abstract | Adherence to cardioprotective medications following myocardial infarction (MI) is commonly assessed using a binary threshold of 80%. We investigated the relationship between medication adherence as a continuous measure and outcomes in MI survivors using restricted cubic splines (RCS). We identified all patients aged >=65 years hospitalised for MI from 2003-2008 who survived one-year post-discharge (n = 5938). Adherence to statins, beta-blockers, renin angiotensin system inhibitors (RASI) and clopidogrel was calculated using proportion of days covered to one-year post-discharge (landmark date). Outcomes were 1-year all-cause death and major adverse cardiac events (MACE) after the landmark date. Adherence-outcome associations were estimated from RCS Cox regression models. RCS analyses indicated decreasing risk for both outcomes above 60% adherence for statins, RASI and clopidogrel, with each 10% increase in adherence associated with a 13.9%, 12.1% and 18.0% decrease respectively in adjusted risk of all-cause death (all p<0.02). Similar results were observed for MACE (all p<0.03). Beta-blockers had no effect on outcomes at any level of adherence. In MI survivors, increasing adherence to statins, RASI, and clopidogrel, but not beta blockers, is associated with a decreasing risk of death/MACE with no adherence threshold beyond 60%. Medication adherence should be considered as a continuous measure in outcomes analyses. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | NLM (Medline) | en |
dc.relation.ispartof | Scientific Reports | - |
dc.title | Cardioprotective medication adherence in Western Australians in the first year after myocardial infarction: restricted cubic spline analysis of adherence-outcome relationships. | en |
dc.type | Article | en |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1038/s41598-020-60799-5 | - |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 32152400 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32152400] | en |
dc.identifier.source | 633526233 | en |
dc.identifier.institution | (Greenland, Knuiman, Nedkoff, Sanfilippo) School of Population and Global Health, University of Western Australia, Perth, WA, Australia (Hung) Medical School, University of Western Australia, Perth, WA, Australia (Arnet) Department of Pharmaceutical Sciences, Pharmaceutical Care Research Group, University of Basel, Basel, Switzerland (Rankin) Cardiology Department, Fiona Stanley Hospital, Murdoch, WA, Australia (Kilkenny) School of Clinical Sciences Monash Health, Monash University, Melbourne, VIC, Australia (Kilkenny) Stroke Division, University of Melbourne, Florey Institute of Neuroscience and Mental Health, VIC, Australia | en |
dc.rights.statement | This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine | en |
dc.identifier.authoremail | Sanfilippo F.M.; frank.sanfilippo@uwa.edu.au | en |
dc.identifier.affiliationext | (Greenland, Knuiman, Nedkoff, Sanfilippo) School of Population and Global Health, University of Western Australia, Perth, WA, Australia | - |
dc.identifier.affiliationext | (Hung) Medical School, University of Western Australia, Perth, WA, Australia | - |
dc.identifier.affiliationext | (Arnet) Department of Pharmaceutical Sciences, Pharmaceutical Care Research Group, University of Basel, Basel, Switzerland | - |
dc.identifier.affiliationext | (Rankin) Cardiology Department, Fiona Stanley Hospital, Murdoch, WA, Australia | - |
dc.identifier.affiliationext | (Kilkenny) Stroke Division, University of Melbourne, Florey Institute of Neuroscience and Mental Health, VIC, Australia | - |
dc.identifier.affiliationmh | (Kilkenny) School of Clinical Sciences Monash Health, Monash University, Melbourne, VIC, Australia | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.